Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07484022 · ClinicalTrials.gov registry record · Phase 1
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
A Phase 1 study, sponsored by Generate Biomedicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT07484022 is a Phase 1 study that is actively recruiting participants, run by Generate Biomedicines. The registered enrollment target is 37 participants.
The verdict
NCT07484022, a Phase 1 study, is actively recruiting participants, sponsored by Generate Biomedicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of an investigational drug called GB-4362 when it is given together with enfortumab vedotin and pembrolizumab in adults with advanced or metastatic urothelial cancer. GB-4362 is a monoclonal antibody designed to bind and neutralize free monomethyl auristatin E (MMAE), a chemotherapy payload released from enfortumab vedotin that is associated with side effects such as peripheral neuropathy.
Interventions
- DRUG Pembrolizumab
- DRUG enfortumab vedotin (EV)
- DRUG GB-4362
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07484022
The ClinicalTrials.gov registry entry for NCT07484022 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Generate Biomedicines, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT07484022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07484022 about?
NCT07484022 is a clinical study titled "Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer". The purpose of this study is to evaluate the safety and tolerability of an investigational drug called GB-4362 when it is given together with enfortumab vedotin and pembrolizumab in adults with advanced or metastatic urothelial cancer. GB-4362 is a monoclonal antibody designed to bind and neutralize...
What is the current status of trial NCT07484022?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2026-06. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07484022?
The interventions under investigation include: Pembrolizumab (DRUG), enfortumab vedotin (EV) (DRUG), GB-4362 (DRUG).
Who is sponsoring clinical trial NCT07484022?
This trial is sponsored by Generate Biomedicines, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.